Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rabeprazole + cinitapride
- Development stage
- Unknown
- Lead developer
- Solariz Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cintasol-R is a fixed-dose combination pharmaceutical product developed by Solariz Healthcare, containing the proton pump inhibitor rabeprazole (20 mg) and the prokinetic agent cinitapride (3 mg) in a sustained-release formulation. Rabeprazole acts by irreversibly inhibiting the H+/K+-ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion. Cinitapride is a substituted benzamide that enhances gastrointestinal motility by acting as a selective 5-HT4 receptor agonist and a 5-HT2 receptor antagonist, while also possessing 5-HT1 receptor agonist activity. This combination is primarily indicated for the treatment of gastroesophageal reflux disease (GERD) and functional dyspepsia, where both acid suppression and improved gastric emptying are therapeutically beneficial.
- Brand names
- Cintasol-R
- Other names
- Rabeprazole 20 mg + Cinitapride 3 mg SR
02
Targets
5-HT2 (5-HT2 receptor family)5-HT1R (5-HT1 receptor family)ATP4A (Potassium–transporting ATPase alpha chain 1)HTR4 (5-Hydroxytryptamine receptor 4)
Beyond the preview
Go deeper on rabeprazole + cinitapride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rabeprazole + cinitapride.